
Last updated: 2026-09-20 23:01:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Neuphoria Therapeutics Inc. (NEUP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.74, with a market capitalization of $20.00M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.19 to $21.40. This page covers its latest market performance, valuation, price trends and company information.
$20.00M | |
$3.72 | |
$21.40 | |
$2.90 | |
$3.72 | |
8.60K | |
186.95K | |
-- | |
$21.40 | |
$3.19 | |
-- | |
-- |
Neuphoria Therapeutics Inc. (NEUP) last closed at $3.72 as of 2026-09-18 23:31:00, unchanged from the previous close of $3.72.
During the latest regular trading session, NEUP traded between $2.90 and $21.40, with a volume of 8.60K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Neuphoria Therapeutics Inc. (NEUP) moved from $3.73 to $3.74, representing a gain of 0.16% ($0.01).
The stock traded between $3.69 and $3.84 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 22.85 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.0%
NEUP is currently trading at $3.74, placing it 3.0% of the way from its 52-week low of $3.19 to its 52-week high of $21.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neuphoria Therapeutics Inc. (NEUP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.